Calcium antagonists and mortality in patients with coronary artery disease: A cohort study of 11,575 patients

被引:92
作者
Braun, S
Boyko, V
Behar, S
ReicherReiss, H
Shotan, A
Schlesinger, Z
Rosenfeld, T
Palant, A
Friedensohn, A
Laniado, S
Goldbourt, U
机构
[1] NEUFELD CARDIAC RES INST, TEL HASHOMER, ISRAEL
[2] ASSAF HAROFE HOSP, ZERIFIN, ISRAEL
[3] CENT HAEMEK HOSP, AFULA, ISRAEL
[4] CARMEL HOSP, HAIFA, ISRAEL
[5] BARZILAI GOVT HOSP, ASHQELON, ISRAEL
[6] BEILINSON MED CTR, IL-49100 PETAH TIQWA, ISRAEL
[7] BNEI ZION HOSP, HAIFA, ISRAEL
[8] EDITH WOLFSON MED CTR, HOLON, ISRAEL
[9] HASHARON HOSP, IL-49372 PETAH TIQWA, ISRAEL
[10] HILIEL YAFFE HOSP, HADERA, ISRAEL
[11] ISHILOV HOSP, SORASKY MED CTR, TEL AVIV, ISRAEL
[12] KAPLAN HOSP, IL-76100 REHOVOT, ISRAEL
[13] MEIR HOSP, SAPIR MED CTR, KEFAR SAVA, ISRAEL
[14] NAHARIA HOSP, NAHARIYYA, ISRAEL
[15] RAMBAM MED CTR, HAIFA, ISRAEL
[16] RIVKA ZIV HOSP, ZFAT, ISRAEL
[17] SHAARE ZEDEK MED CTR, JERUSALEM, ISRAEL
[18] CHAIM SHEBA MED CTR, INST HEART, IL-52621 TEL HASHOMER, ISRAEL
[19] SOROKA MED CTR, IL-84101 BEER SHEVA, ISRAEL
关键词
D O I
10.1016/0735-1097(96)00109-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. This study sought to establish the risk ratio for mortality associated with calcium antagonists in a large population of patients with chronic coronary artery disease. Background. Recent reports have suggested that the use of short-acting nifedipine may cause an increase in overall mortality in patients with coronary artery disease and that a similar effect may be produced by other calcium antagonists, in particular those of the dihydropyridine type. Methods. Mortality data were obtained for 11,575 patients screened for the Bezafibrate Infarction Prevention study (5,843 with and 5,732 without calcium antagonists) after a mean follow-up period of 3.2 years. Results. There were 495 deaths (8.5%) in the calcium antagonist group compared with 410 in the control group (7.2%). The age adjusted risk ratio for mortality was 1.08 (95% confidence interval [CI] 0.95 to 1.24). After adjustment for the differences between the groups in age and gender and the prevalence of previous myocardial infarction, angina pectoris, hypertension, New York Heart Association functional class, peripheral vascular disease, chronic obstructive pulmonary disease, diabetes and current smoking, the adjusted risk ratio declined to 0.97 (95% CI 0.84 to 1.11). After further adjustment for concomitant medication, the risk ratio was estimated at 0.94 (95% CI 0.82 to 1.08). Conclusions. The current analysis does not support the claim that calcium antagonist therapy in patients with chronic coronary artery disease, whether myocardial infarction survivors or others, harbors an increased risk of mortality.
引用
收藏
页码:7 / 11
页数:5
相关论文
共 25 条
[1]   USE OF CALCIUM-CHANNEL BLOCKING-AGENTS IN THE MANAGEMENT OF ISCHEMIC HEART-DISEASE [J].
BRAUNWALD, E ;
MULLER, JE ;
STONE, PH .
EUROPEAN HEART JOURNAL, 1985, 6 :31-34
[2]  
CONE PF, 1984, AM J CARDIOL, V63, P534
[3]  
COX DR, 1972, J R STAT SOC B, V34, P187
[4]   CALCIUM-ANTAGONISTS IN THE MANAGEMENT OF SYSTEMIC HYPERTENSION - THE IMPACT OF SUSTAINED-RELEASE DRUG-DELIVERY SYSTEMS [J].
FRISHMAN, WH ;
ROSENBERG, A ;
KATZ, B .
CORONARY ARTERY DISEASE, 1994, 5 (01) :4-13
[5]   NIFEDIPINE - DOSE-RELATED INCREASE IN MORTALITY IN PATIENTS WITH CORONARY HEART-DISEASE [J].
FURBERG, CD ;
PSATY, BM ;
MEYER, JV .
CIRCULATION, 1995, 92 (05) :1326-1331
[6]   RATIONALE AND DESIGN OF A SECONDARY PREVENTION TRIAL OF INCREASING SERUM HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL AND REDUCING TRIGLYCERIDES IN PATIENTS WITH CLINICALLY MANIFEST ATHEROSCLEROTIC HEART-DISEASE (THE BEZAFIBRATE INFARCTION PREVENTION TRIAL) [J].
GOLDBOURT, U ;
BEHAR, S ;
REICHERREISS, H ;
AGMON, J ;
KAPLINSKY, E ;
GRAFF, E ;
KISHON, Y ;
CASPI, A ;
WEISBORT, J ;
MANDELZWEIG, L ;
ABINADER, E ;
AHARON, L ;
BRAUN, S ;
DAVID, D ;
FLICH, M ;
FRIEDMAN, Y ;
KRISTAL, N ;
LEIL, N ;
MARKIEWICZ, W ;
MARMOR, A ;
PALANT, A ;
PELLED, B ;
RABINOWITZ, B ;
REISIN, L ;
ROGUIN, N ;
ROSENFELD, T ;
SCHLESINGER, Z ;
SCLAROVSKY, S ;
SHERF, L ;
TZIVONI, D ;
ZAHAVI, I ;
ZION, M ;
BRUNNER, D ;
FRIDENSOHN, A ;
JAFARI, J ;
OSTFELD, B ;
ROCHFLEISH, S ;
SCHNEIDER, H ;
KHALID, S ;
NARINSKY, R ;
ROTZAK, R ;
VITRAI, J ;
PELLED, B ;
PARDU, J ;
LANIADO, S ;
ESHCHAR, Y ;
ARDITI, A ;
BOTWIN, S ;
ROGUIN, N ;
YAHALOM, M .
AMERICAN JOURNAL OF CARDIOLOGY, 1993, 71 (11) :909-915
[7]   EARLY ADMINISTRATION OF NIFEDIPINE IN SUSPECTED ACUTE MYOCARDIAL-INFARCTION - THE SECONDARY PREVENTION REINFARCTION ISRAEL NIFEDIPINE TRIAL-2 STUDY [J].
GOLDBOURT, U ;
BEHAR, S ;
REICHERREISS, H ;
ZION, M ;
MANDELZWEIG, L ;
KAPLINSKY, E .
ARCHIVES OF INTERNAL MEDICINE, 1993, 153 (03) :345-353
[8]   CALCIUM-CHANNEL BLOCKERS IN ACUTE MYOCARDIAL-INFARCTION AND UNSTABLE ANGINA - AN OVERVIEW [J].
HELD, PH ;
YUSUF, S ;
FURBERG, CD .
BMJ-BRITISH MEDICAL JOURNAL, 1989, 299 (6709) :1187-1192
[9]  
JACKSON G, 1995, BR J CLIN PHARM, V19, P283
[10]   NIFEDIPINE IN ISCHEMIC-HEART-DISEASE [J].
KLONER, RA .
CIRCULATION, 1995, 92 (05) :1074-1078